A Phase I/III Clinical Study of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear

A Multi-center, Randomized, Independent Evaluator-Subject Blinded, Placebo-Controlled, Phase I/III Clinical Study to Evaluate Safety and Efficacy of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03668028

Enrollment

Registered

2018-09-12

Start date

2018-07-09

Completion date

2022-04-28

Last updated

2023-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotator Cuff Injuries

Brief summary

Rotator cuff tear is one of the most common shoulder diseases and retears occur frequently after arthroscopic repair. Therefore, there is a growing need of new therapy to improve structural outcome. This study evaluates the efficacy and safety of autologous fibroblasts during arthroscopic repair. The primary outcome is the retear rate at 24 weeks after administration of autologous fibroblasts (TPX-114) during arthroscopic repair. Secondary outcomes are functional evaluations including Range of Motion (ROM), Constant Score (CS), American Shoulder and Elbow Surgeons (ASES) score and Simple Shoulder Test (SST) at 24 and 52 weeks after administration.

Interventions

BIOLOGICALTPX-114

Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.

PROCEDUREArthroscopic surgery

Subjects undergo conventional arthroscopic surgery for rotator cuff repair.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

Participants must; 1. Be 19 years of age or older. 2. Require arthroscopic repair for full-thickness rotator cuff tear(\>2cm, ≤5cm) assessed by MRI without improvement of symptoms despite more than 3 months of conservative management. 3. Consent to undergo skin biopsy to manufacture test product. 4. Understand fully the study and voluntarily sign the informed consent for participation in the study.

Exclusion criteria

Participants with any of the following conditions will be excluded unless stated otherwise; 1. Unsuitable for skin biopsy. 2. Have additional subscapularis tear. 3. Have prior medical history of the following at the time of screening. * Operation of the affected shoulder * Allergies to bovine proteins * Anaphylaxis to gentamicin * Coagulopathy * Genetic disorders affecting fibroblasts or collagen (ex. achondroplasia, osteogenesis imperfecta) * Malignant tumors within the last 5 years 4. Have been diagnosed with any of the following diseases at the time of screening. * Autoimmune disease (including RA) * HIV Ab-positive * Acute trauma, chronic shoulder dislocation, pyogenic infection on the affected shoulder * Scapulohumeral osteoarthritis 5. Be pregnant, breastfeeding, planning pregnancy or unwilling to use of contraceptives suggested in this study. 6. Other surgical or nonsurgical procedures on the affected shoulder to be judged more appropriate than arthroscopic repair. 7. Have participated in and received investigational agents in other clinical trials within 4 weeks of this study. 8. Be deemed inadequate for the study by investigators.

Design outcomes

Primary

Measure	Time frame	Description
Retear Rate	24 weeks	Retear rate assessed by an independent evaluator with MRI

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026